Synbiotic Composition for Caesarean-Section Infant Microbiota
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Infants delivered by Caesarean section often experience delayed or aberrant colonization of Bifidobacteria in their gut microbiota, leading to increased risks of diarrhea, allergic sensitization, and potential development of obesity, which is not naturally established like in vaginally delivered, breast-fed infants.
Innovation Solution
The co-administration of a specific probiotic strain of Lactobacillus rhamnosus with an oligosaccharide mixture comprising N-acetylated, neutral, and sialylated oligosaccharides promotes early bifidogenic intestinal microbiota in Caesarean-born infants, mimicking the healthy gut flora of vaginally delivered babies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Caesarean section delivery is performed, then birth can be achieved in cases of obstetric complications, but delayed or aberrant colonization of Bifidobacteria occurs in the infant gut
Solution Approach 1:
The patent applies preliminary action by administering a synbiotic composition containing specific probiotic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis BB-12) and prebiotic oligosaccharides to Caesarean-born infants immediately after birth. This preliminary intervention compensates for the absence of natural vaginal delivery colonization, establishing beneficial Bifidobacteria dominance in the gut microbiota from the outset, thereby resolving the delayed/aberrant colonization issue while maintaining the safety benefits of Caesarean delivery.
2Reliability
If probiotic bacteria are added to infant formula, then beneficial colonization is promoted, but concerns are raised about safety and appropriateness for infants in the first six months
Solution Approach 1:
The patent employs the composite materials principle by creating a synbiotic composition that combines specific probiotic bacteria strains (Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis BB-12) with carefully selected prebiotic oligosaccharides (GOS, FOS, inulin) in defined proportions. This composite approach enhances the safety and efficacy of probiotic administration to infants by providing a synergistic formulation that supports beneficial gut colonization while addressing safety concerns through the use of well-tolerated, naturally occurring components in age-appropriate doses.
3Reliability
If Bifidobacteria domination is established in the gut, then intestinal barrier development is promoted and absorption is enhanced, but this natural pattern is not established in Caesarean-born infants
Solution Approach 1:
The patent applies preliminary action by introducing specific probiotic strains and prebiotics to Caesarean-born infants immediately after birth, before the gut microbiota becomes established. This early intervention promotes the development of Bifidobacteria domination and intestinal barrier function from the outset, compensating for the absence of natural vaginal delivery colonization and preventing delayed development of these critical protective mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces the risk of subsequent allergy development and diarrhea in Caesarean-section infants by priming their gastrointestinal tract for beneficial Bifidobacteria colonization, similar to that of healthy, breast-fed, vaginally delivered infants.
Implementation Method 1
A prebiotic is a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon
Implementation Method 2
specific strains of the genera Lactobacilli and Bifidobacteria have been found to be able to colonise the intestine, to reduce the capability of pathogenic bacteria to adhere to the intestinal epithelium
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The use of a probiotic strain of Lactobacillus rhamnosus and an oligosaccharide mixture which comprises 5-70 wt% of at least one N-acetylated oligosaccharide selected from the group comprising GalNAcal,3Galßl,4Glc and Galßl,6GalNAcal,3Galßl,4Glc, 20-90 wt% of at least one neutral oligosaccharide selected from the group comprising Galßl,6Gal, Galßl,6Galßl,4Glc Galßl,6Galßl,6Glc, Galßl,3Galßl,3Glc, Galß 1,3Galß 1,4GIc, Galß 1,6Galß 1,6Galß 1,4GIc, Galß 1,6Galß 1,3Galß 1,4GIc Galßl,3Galßl,6Galßl,4Glc and Galß l,3Galßl,3Galßl, 4GIc and 5-50 wt% of at least one sialylated oligosaccharide selected from the group comprising NeuAca2,3Galßl,4Glc and NeuAca2,6Galßl,4Glc in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants delivered by caesarean section is disclosed.